Type 2 3a-hydroxysteroid dehydrogenase (3a-HSD) is a multi-functional enzyme that possesses 3a-, 17b-and 20a-HSD, as well as prostaglandin (PG) F synthase activities and catalyzes androgen, estrogen, progestin and PG metabolism. Type 2 3a-HSD was cloned from human prostate, is a member of the aldo-keto reductase (AKR) superfamily and was named AKR1C3. In androgen target tissues such as the prostate, AKR1C3 catalyzes the conversion of D 4 -androstene-3,17-dione to testosterone, 5a-dihydrotestosterone to 5a-androstane-3a,17b-diol (3a-diol), and 3a-diol to androsterone. Thus AKR1C3 may regulate the balance of androgens and hence transactivation of the androgen receptor in these tissues. Tissue distribution studies indicate that AKR1C3 transcripts are highly expressed in human prostate. To measure AKR1C3 protein expression and its distribution in the prostate, we raised a monoclonal antibody specifically recognizing AKR1C3. This antibody allowed us to distinguish AKR1C3 from other AKR1C family members in human tissues. Immunoblot analysis showed that this monoclonal antibody binds to one species of protein in primary cultures of prostate epithelial cells and in LNCaP prostate cancer cells. Immunohistochemistry with this antibody on human prostate detected strong nuclear immunoreactivity in normal stromal and smooth muscle cells, perineurial cells, urothelial (transitional) cells, and endothelial cells. Normal prostate epithelial cells were only faintly immunoreactive or negative. Positive immunoreactivity was demonstrated in primary prostatic adenocarcinoma in 9 of 11 cases. Variable increases in immunoreactivity for AKR1C3 was also demonstrated in non-neoplastic changes in the prostate including chronic inflammation, atrophy and urothelial (transitional) cell metaplasia. We conclude that elevated expression of AKR1C3 is highly associated with prostate carcinoma. Although the biological significance of elevated AKR1C3 in prostatic carcinoma is uncertain, AKR1C3 may be responsible for the trophic effects of androgens and/or PGs on prostatic epithelial cells.
Introduction
Androgens are critical for maintaining normal function of the prostate gland and are also trophic factors for the development of human prostate carcinoma (CaP) (Isaacs et al. 1994) . The orchestrated expression of androgen-metabolizing enzymes including 5a-reductase type 2, 17b-hydroxysteoid dehydrogenase (HSD), 3a-HSD and 3b-HSD is critical to maintain the balance of different androgen metabolites within the prostate to maintain its normal physiological function. The type 2 3a-HSD was cloned from a human prostate cDNA library by us (Lin et al. 1997) , was found to belong to the aldo-keto reductase (AKR) superfamily, and was designated AKR1C3. AKR1C3 possesses 3a-HSD, 17b-HSD, 20a-HSD and prostaglandin (PG) F synthase activities and catalyzes androgen, estrogen, progesterone and PG metabolism (Dufort et al. 1996 , Lin et al. 1997 , Matsuura et al. 1998 , Penning et al. 2001 . AKR1C3, therefore, has the capability of regulating ligand access to multiple nuclear receptors including the androgen receptor (AR), estrogen receptor, progesterone receptor and peroxisome proliferator activated receptor gamma (PPARg) in endocrine peripheral tissues.
In androgen metabolism, AKR1C3 catalyzes the reductive reaction of 5a-dihydrotestosterone (5a-DHT) to 5a-androstane-3a,17b-diol (3a-diol) by its 3a-HSD activity (Lin et al. 1997 ) and the conversion of D 4 -androstene-3,17-dione (D 4 -dione) to testosterone by its 17b-HSD activity (Labrie et al. 2000a) (Fig. 1 ). 5a-DHT and testosterone are active androgens in the prostate, and responsible for physiological and pathological development of the gland. It has been assumed that 3a-diol has no androgenic effects unless it is first oxidized back to 5a-DHT (Jacobi et al. 1978 , Mahendroo et al. 1996 , Wilson et al. 2003a . We recently reported that 3a-diol may stimulate prostate cell proliferation through an AR-independent, epidermal growth factor-like pathway(s) , Zimmerman et al. 2004 . These results would be consistent with previous reports describing 3a-diolinduced prostate enlargement in a castrated dog model (Jacobi et al. 1978) , 3a-diol-regulated male urogenital tract development in the fetus of the pouch of female marsupials (Wilson et al. 2003b) , and 3a-diol-induced parturition in a mouse model (Mahendroo et al. 1996) . AKR1C3, therefore, can be a candidate enzyme in regulating the activation of AR or growth factor signaling pathways through local accumulation of testosterone, 5a-DHT, or 3a-diol for prostate growth.
In PG metabolism, AKR1C3 catalyzes the 11-keto-reduction of PGD 2 to yield the PGF 2a epimer, 9a,11b-PGF 2a , thereby depriving PPARg of its putative ligand 15D-PGJ 2 (Desmond et al. 2003) . In normal prostate, epithelial cells do not express PPARg but in PC-3 prostate cancer cells, which express PPARg, 15DPGJ 2 is growth inhibitory ). 15DPGJ 2 is derived from normal stromal cells and suppresses adjacent tumor growth (Kim et al. 2005) . These growth inhibitory properties may be mediated by downregulation of cyclooxygenase (COX)-2 by 15DPGJ 2 . In vivo, results with COX-2 inhibitors also show a pronounced inhibitory effect on tumor microvessel density and angiogenesis (Kirschenbaum et al. 2001) . In the presence of elevated AKR1C3, PGD 2 will be diverted to its pro-proliferative ligand 9a,11b-PGF 2 . Thus AKR1C3 may also be intimately involved in controlling proliferative growth and vascular development in the diseased prostate.
Tissue and prostate distribution of AKR1C3 has been investigated. Using an AKR1C3 3 0 -UTR as a cDNA probe, transcript expression of AKR1C family members including AKR1C2/AKR1C3 was detected in multiple tissues including prostate (Lin et al. 1997) . Expression of these transcripts was also detected in primary cultures of both prostate epithelial and stromal cells with higher levels of transcript expression in epithelial cells (Lin et al. 1997) . Semi-quantitative AKR1C isoform-specific RT-PCR confirmed the high expression of AKR1C3 in the prostate (Penning et al. 2000) . AKR1C3 has been shown to be expressed in the Leydig cells of the testis as well as prostate basal and luminal epithelial cells using an anti-AKR1C3 polyclonal antibody raised against the C-terminal domain of the protein . Immunoaelectron microscopy shows no association with specific organelles compatible with the cytosolic localization of AKRs (Pelletier et al. 2001 ) but some nuclear staining was noted.
To further study AKR1C3 protein expression in the prostate, we developed and characterized a mouse anti-human 3a-HSD monoclonal antibody (mAb; clone NP6G6.A6). This mAb is monospecific against AKR1C3 ) and does not cross-react with AKR1C1, AKR1C2 or AKR1C4. In this report, we extend our investigation of AKR1C3 distribution in CaP tissues. High levels of immunoreactivity were observed in all endothelial cells in the prostate with staining in some stromal cells. In contrast to low immunoreactivity in normal prostate epithelium, strong positive staining was detected in the epithelium of the majority of CaP cases along with other prostate pathologies. Elevated AKR1C3 expression in human CaP may result in an imbalance of androgen metabolism in the prostate, which may lead to abnormal prostate growth through de-regulated trans-activation of nuclear receptors (AR and PPARg).
Materials and methods

Reagents
Mouse anti-human AR mAb was acquired from Vector Laboratories (Burlingame, CA, USA). Mouse anti-human type 2 3a-HSD (AKR1C3) mAb was prepared at the Cell Center, University of Pennsylvania School of Medicine as previously described using the full-length recombinant AKR1C3 protein as the antigen ). Kenneth's HY, RPMI 1640, keratinocyte serum-free medium (K-SFM), and fetal bovine serum (FBS) were purchased from Invitrogen (Carlsbad, CA, USA), and ORIGEN hybridoma cloning factor was obtained from IGN International (Gaithersburg, MD, USA). Charcoal/dextran-treated FBS was purchased from HyClone (Logan, UT, USA). Hematoxylin and eosin were purchased from Sigma (St Louis, MO, USA). Biotinylated goat anti-mouse 
Cell Culture
Human prostate LNCaP cells were obtained from ATCC and maintained in growth medium consisting of RPMI 1640 medium supplemented with 10% FBS, 100 units/ml penicillin and 100 mg/ml streptomycin (Invitrogen) in a humidified cell incubator at 37 C in 5% CO 2 . Primary cultures of prostate cells were prepared from prostate following surgical radical prostatectomy as described by Lang et al. (2001) . Primary cultures of prostate cells were established and maintained in K-SFM supplemented with 1% charcoal/dextran-treated FBS.
The hybridoma line that produces anti-human AKR1C3 mAb was maintained in hybridoma growth media consisting of Kenneth's HY, 20% FBS, 2% hybridoma cloning factor, 4 mM L-glutamine and 1% OPI Media Supplement (Sigma).
Western blot analysis
Cellular proteins were prepared from LNCaP cells and from primary cultures of prostate epithelial cells in a modified RIPA buffer (50 mM Tris-HCl (pH 7.4), 1% NP-40, 0.25% sodium deoxycholate, 150 mM NaCl, 1 mM EDTA and 2 mM phenylmethylsulfonyl fluoride). Total soluble proteins (30 mg) were electrophoresed on a 12% Tris-HCl gel (Bio-Rad). Proteins were transferred onto polyvinylidene difluoride (PVDF) membranes (Bio-Rad). The membranes were blocked with 5% non-fat dry milk (Bio-Rad) in Trisbuffered saline containing 1% Tween 20. Antigens were detected by incubating with mouse anti-human AKR1C3 mAb (1 : 500) or anti-b-actin mAb (1 : 5000; Sigma) at room temperature for 2 h followed by incubation with HRP-conjugated anti-mouse IgG (1 : 125 000; KPL, Gaithersburg, MD, USA) secondary antibody at room temperature for another 1 h. Immunoreactive protein was then detected using enhanced chemiluminescence reagent (Pierce, Rockford, IL, USA) according to the manufacturer's protocol.
RT-PCR analysis of AKR1C3 mRNA
Amplification of AKR1C3 and b-actin mRNA was performed using AKR1C3 isoform-specific primers (Penning et al. 2000) from total RNA isolated from LNCaP cells and primary cultures of prostate epithelial cells.
Human prostate tissues
Archival formalin-fixed, paraffin-embedded prostate tissue blocks and their associated clinical information were acquired from the Department of Pathology, University of Oklahoma Health Sciences Center in accordance with an approved Institutional Review Board protocol.
All of the prostate glands were obtained through radical prostatectomy. A total of 11 cases of CaP were used in this study (Table 1) . Prostate tissue that was free of carcinoma was obtained from an additional case (radical cystoprostatectomy) and used as a control. The diagnoses were rendered by four pathologists (B B, C Z L, J T Y and K M F) and reviewed by one of the pathologists (K M F). Semi-serial paraffin sections were cut at 4-6 mm, dried at 55 C overnight, and stored at x20 C until use. Slides were deparaffinized with xylene and rehydrated in graded ethanol before use as previously described .
Hematoxylin-eosin stain
Deparaffinized and rehydrated slides were stained in hematoxylin and blued in lithium carbonate solution. The slides were then washed, stained with eosin, washed, dehydrated and sealed with Permount Mounting Media (Sigma).
Immunohistochemistry (IHC) of human prostate tissue sections
IHC was performed with a three-step, peroxidasemediated mechanism as previously described (Fung et al. 1995) . Briefly, deparaffinized and rehydrated tissue sections were incubated with 0.5% H 2 O 2 in methanol for 10 min to block endogenous peroxidase activity. Antigen retrieval was performed by heating the slides in 10 mM citric acid buffer (pH 6.0) in a microwave oven at 1200 W for 20 min. The slides were then washed with 0.1 M Tris-HCl at pH 7.6 (TRIS) for 5 min and then incubated with TRIS containing 10% goat serum to block non-specific binding. Slides were then incubated with AKR1C3 mAb (NP6G6.A6) at a dilution of 1 : 200 of at 4 C overnight. After washing with TRIS, the slides were incubated with biotinylated goat anti-mouse secondary antibody in TRIS containing 10% goat serum at room temperature for 1 h. Following washes with TRIS, HRP-conjugated streptavidin diluted in TRIS containing 10% goat serum was added to slides and incubated at room temperature for another 40 min. The slides were washed in TRIS for 10 min. A DAB-H 2 O 2 substrate was added to the slides and incubated at room temperature for 6 min. Slides were then washed with distilled water and counterstained with hematoxylin. Slides were dehydrated and sealed with Permount Mounting Media for visualization.
Scoring of IHC for AKR1C3-positive cancer cells
The percentage of positively immunoreactive cells with IHC staining was evaluated and graded into five categories: over 75% positive (>75%), 50% positive (50%), 25% positive (25%), 10% positive (10%) and negative (0%).
Results
Detection of AKR1C3 in cultured human prostate cells
We have previously reported the monospecificity of the mAb (NP6G6.A6) and shown that it only recognizes recombinant AKR1C3 among members of the AKR1C family . To demonstrate the ability of this antibody to specifically distinguish AKR1C3 from other cellular proteins, Western blot analysis was performed in total cellular lysates prepared from primary cultures of prostate epithelial cells (normal and CaP) and from androgen-sensitive human prostate cancer LNCaP cells. A single protein species with a molecular mass of approximately 37 kDa was detected in these total cellular protein preparations (Fig. 2B) . The recognized protein species had the same size as the recombinant AKR1C3 protein (Lin et al. 1997 . To correlate the levels of AKR1C3 protein expression with its transcript expression in the cultured prostate cells, AKR1C3 mRNA was amplified using our established RT-PCR procedures using the isoform-specific primer sets for AKR1C3 (Penning et al. 2000) . The results showed comparable www.endocrinology-journals.org levels of AKR1C3 protein and transcript expression in these cells ( Fig. 2A) .
Immunoreactivity of AKR1C3 enzyme protein in normal prostate
The mAb for AKR1C3 was used for immunohistochemical (IHC) detection of AKR1C3 protein in human prostate tissue. Consistently strongly nuclear and cytoplasmic immunoreactivity of the mAb was demonstrated in the endothelial cells and perineurial cells (Fig. 3A and B) . Variable immunoreactivity was demonstrated in the stromal cells and smooth muscle cells. The glandular epithelial cells were either faintly immunoreactive or non-immunoreactive. Strong nuclear and cytoplasmic immunoreactivity was also demonstrated in urothelial (transitional) cells in the prostatic urethra (Fig. 3C) . Predominantly cytoplasmic immunoreactivity was demonstrated in the seminal vesicles (Fig. 3D) .
Immunoreactivity of AKR1C3 enzyme protein in CaP
Positive immunoreactivity was identified in 9 of 11 cases (81.8%) of CaP (Table 1) . In general, a variable percentage of carcinomatous cells in these nine CaP cases was positive. There was no single case in which all the carcinomatous cells were positive but five of the nine cases (55.6%) had positive immunoreactivity in over 50% of the carcinomatous cells (Table 1) . Both cytoplasmic and nuclear immunoreactivity were demonstrated in the carcinomatous cells ( Fig. 4A and B). Variation from strong to negative immunoreactivity was demonstrated within the same tumor ( Fig. 4B and C) and also among different tumors ( Fig. 4D and E) . In Cases No. 1 and No. 9, strong immunoreactivities were predominantly found in cribiform areas that corresponded to a Gleason score of 4, while negative immunoreactivity was found in invasive carcinoma with small glands that corresponded to a Gleason score of 3 ( Fig. 4D and E) . This pattern of expression was not demonstrated in other tumors that had both cribiform and small gland invasive components. In areas with positive immunoreactivity, it was more often the case to demonstrate positive immunoreactivity in all neoplastic cells within the same gland ( Fig. 4B and D) . A less common pattern was that individual immunoreactive carcinomatous cells existed within a background of non-immunoreactive carcinomatous cells (Fig. 4F) .
Immunoreactivity of AKR1C3 enzyme protein in non-neoplastic conditions
Focally positive immunoreactivity was also demonstrated in benign glands in areas with chronic inflammation (Fig. 5A ). Similar focally positive immunoreactivity was also demonstrated in glands with atrophic changes (Fig. 5B) . Positive immunoreactivity was demonstrated in glandular epithelium with urothelial (transitional) cell metaplasia (Fig. 5C ). In contrast, glandular epithelium with basal cell hyperplasia were non-immunoreactive (Fig. 5D ).
Relationship between immunoreactivity of AKR1C3 and AR IHC staining for AR was performed on sections adjacent to those that had been used for AKR1C3 IHC staining. Both carcinomatous and non-neoplastic prostate gland epithelial cells were immunoreactive for AR. No correlation in staining patterns was observed between AR-positive immunostaining and positive or negative immunoreactivity for AKR1C3 in CaP (Fig. 6 ).
Discussion
An isoform-specific, mouse anti-human mAb (clone NP6G6.A6) that recognizes AKR1C3 but not other members of the AKR1C family has been developed by us . In this study, we demonstrated that this mAb can recognize AKR1C3 specifically in total cell lysates obtained from primary cultures of human prostate epithelial cells and human prostate cancer LNCaP cells by western blot analysis. One purpose in the report is to demonstrate that the AKR1C3 mAb can recognize a single species of protein in human prostate-derived cells. Detection of AKR1C3 transcripts by RT-PCR in these cells showed parallel expression of AKR1C3 mRNA and protein in human prostate cells. This antibody was used to study the expression of AKR1C3 in neoplastic and non-neoplastic prostate tissue through IHC. Our results showed cytoplasmic immunoreactivity of AKR1C3 in non-epithelial components of the prostate including endothelial cells, perineurial cells, stromal and smooth muscle cells. Immunoreactivity was also demonstrated in urothelial (transitional) epithelium in the prostatic urethra and also in epithelial cells of seminal vesicles. In contrast, normal prostatic glandular epithelial cells showed only faint or total absence of immunoreactivity with this isoform-specific antibody. Positive cytoplasmic immunoreactivity for AKR1C3 was detected in 9 of 11 CaP cases. We conclude that AKR1C3 is upregulated in CaP. Increased AKR1C3 immunoreactivity in adenocarcinoma cells is in accord with our previous observation that elevated reductive 3a-HSD enzymes, such as AKR1C2 (Rizner et al. 2003) and ARK1C3 (Lin et al. 1997) show increased transcript expression in primary cultures of prostate epithelial cells derived from cancerous sections of the prostate.
Surprisingly, we also observed positive nuclear immunoreactivity for AKR1C3. However, this result is consistent with an immunoelectron microscopic study of this enzyme reported by Pelletier et al. (2001) , although these authors did not emphasize Endocrine-Related Cancer (2006) 13 169-180 www.endocrinology-journals.org nuclear localization of this enzyme. It is possible that nuclear AKR1C3 performs a yet unknown function. We have ruled out that the nuclear staining is an artifact of antigen retrieval, since the same staining pattern is observed in the presence and absence of antigen retrieval. It is also possible that the nuclear staining is due to the diffusion of AKR1C3 to the nucleus during the sample handling. However, Pelletier observed the nuclear staining following rapid processing of the prostate tissue.
Co-localization of AKR1C3 and AR was also investigated in normal prostate and CaP specimens. Consistent with previous reports (Chodak et al. 1992 , El-Alfy et al. 1999 , Labrie et al. 2000b , AR shows a strong nuclei staining pattern. Our data demonstrated that AKR1C3 and AR are co-expressed in the same cell types in prostate tissue, particularly in cases of CaP. However, the increased immunoreactivity of AKR1C3 in CaP cases is not associated with a change in immunoreactivity of AR as evaluated by IHC. Although there appears to be no correlation between AKR1C3 and AR expression in CaP using IHC staining, their co-localization in CaP still supports our hypothesis that AKR1C3 may regulate androgen access to the AR.
Tissue distribution of AKR1C3 has been studied in human reproductive organs including prostate and breast. Using a rabbit polyclonal antibody that was raised against the C-terminal of AKR1C3, El-Alfy et al. (1999) demonstrated positive immunoreactivity in stromal and endothelial cells in the prostate. A similar pattern of positive immunoreactivity in prostate stromal and endothelial cells was observed in our study. However, El-Alfy et al. demonstrated positive immunoreactivity in the glandular basal cells but not the luminal epithelial cells. In our study, however, most of the luminal and basal epithelial cells of prostatic glands were negative or, at most, faintly immunoreactivity. The causes of discrepancies between these two studies are not clear. It may reflect difference in the cross-reactivity of the two antibodies. Our mAb is specific for AKR1C3, while the polyclonal antibody for AKR1C3 may cross-react with AKR1C1, which is expressed in the prostate (D M Bauman and T M Penning, unpublished observations).
Multiple hypotheses exist to explain the elevated AKR1C3 expression in CaP and a role of this enzyme in the pathogenesis of CaP. First, with its type 5 17b-HSD activity, AKR1C3 can generate the local source of potent androgen by converting D 4 -dione to testosterone (Labrie et al. 2000a) . The subsequent intraprostatic accumulation of testosterone can serve as substrate for type 2 5a-reductase, enhance AR trans-activation activity, and act as a growth advantage for the adenocarcinoma even in the absence of elevated AR protein expression.
Secondly, based on our previous observation that 3a-diol can stimulate prostate cell proliferation through an AR-independent, growth factor-like pathway(s) in vitro , Zimmerman et al. 2004 , it is possible that AKR1C3 converts the potent androgen, 5a-DHT, into its cognate metabolite, 3a-diol, and regulates the utilization of AR or growth factor receptor signaling pathways in the prostate. Growing evidence suggests 3a-diol might be an important hormone with its own androgenic effects in hormone target organs through yet undefined pathway(s). It has been suggested that 3a-diol is a more potent androgen than 5a-DHT or testosterone in inducing prostatic hyperplasia in the castrated dog (Walsh & Wilson 1976 , Jacobi et al. 1978 and may be more effective than 5a-DHT in virilizing the urogenital tract including prostate both in the fetal rat (Schultz & Wilson 1974 ) and in the fetus of the pouch of female marsupials (Wilson et al. 2003a ,b, Leihy et al. 2004 .
Thirdly, via its 11-ketoprostaglandin reductase activity, AKR1C3 catalyzes the 11-keto-reduction of PGD 2 to yield the PGF 2a epimer, 9a,11b-PGF 2 (Desmond et al. 2003) . This enzymatic function causes AKR1C3 to divert PGD 2 catabolism to 9a,11b-PGF 2a and reduce the accumulation of PGJ 2 , a ligand for PPARg receptor (Desmond et al. 2003) . A functional consequence of PGJ 2 deprivation is that the growth inhibitory effects of 15DPGJ 2 in CaP are attenuated . This also prevents the downregulation of COX-2, which when elevated can have a pronounced effect on microvessel density and angiogenesis in prostatic tumors (Kirschenbaum et al. 2001 . PGD 2 -induced cell proliferation and PGJ 2 -induced differentiation and programmed cell death have been identified in variety of cell types including prostate cancer cells (Butler et al. 2000 , Desmond et al. 2003 , Yee et al. 2003 , Morosetti et al. 2004 , Zang et al. 2004 . Furthermore, the activation of PPARg by a synthetic ligand, troglitazone, suppressed AR trans-activation activity in prostate cancer cells and serum prostate-specific antigen levels in a patient with CaP (Hisatake et al. 2000) . Therefore, elevated expression of AKR1C3 may regulate PG metabolism in the prostate and cause the accumulation of the proliferative PG, 9a,11b-PGF 2a. AKR1C3 may also be intimately involved in controlling proliferative growth and vascular development in the diseased prostate through this pathway. We are actively studying the relationship between AKR1C3 and PPARg expression in CaP.
